



CERTIFICATION UNDER 37 CFR 1.10

EM 168 884 744 US: Express Mail Number

August 25, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

David Botstein, **Audrey Goddard** David A. Lawrence **Diane Pennica Margaret Ann Roy** William I. Wood

Title:

CARDIOTROPHIN-1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF

TUMOR

Type of Application 1.

[]	This application is for an original, non-provisional application.

[]	This is a non-provisional application claiming priority to provisional application no, to	iled
	, the entire disclosure of which is hereby incorporated by reference.	

[x]	This is a [] continuation-in-part [X] continuation [] divisional application
	claiming priority to Application Serial Number 09/234,730, filed 21 January 1999, which is a
	non-provisional application of Application Serial No. 09/033,114, filed March 2, 1998, which
	is a continuation of U.S. Application Serial No. 08/733,850 filed October 18, 1996, now
	abandoned, which is a continuation of U.S. Application Serial No. 08/443,129 filed May 17,
	1995, issued May 6, 1997 as U.S. Patent No. 5,627,073, which is a divisional application of
	U.S. Application Serial No. 08/286,304 filed August 5, 1994, issued November 5, 1996 as
	U.S. Patent No. 5,571,893, which is a continuation-in-part of U.S. Application Serial No.
	08/233,609 filed April 25, 1994, issued July 9, 1996 as U.S. Patent No. 5,534,615, and to
	U.S. Provisional Application Serial No. 60/113,296, filed December 22, 1998, the entire
	disclosure of which is hereby incorporated by reference.



Ħ
Ш
Ħ
Щ
U

<u>6</u>	n-provisional) 1 pages of specification
_2	pages of claims
<u></u> 	page(s) of abstract 3 sheet(s) of drawings
	[] formal [x] informal
Dec	claration or Oath
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) An executed declaration of the inventor(s) [] is enclosed [] will follow.
<u>x</u>	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
	(for Cont./Div. where inventor(s) being deleted)
	A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
Ass	ignment
	(for new and CIP applications)
	An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.
	(for cont./div.)
<u> x</u>	The prior application is assigned of record to Genentech, Inc.
Am	endments (for continuation and divisional applications)
<u>x</u>	Cancel in this application original claims 1-23 of the prior application before calculating the filing fee.
<u>x</u>	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highes numbered original claim in the prior application.)
Rela	ate Back 35 U.S.C. 120 or 35 U.S.C. 119
	Amend the specification by inserting before the first line the sentence:
Th	is is a
	non-provisional application continuation

(C)



Alconced

of co-pending application(s)

Serial No. 09/234,730 filed on 21 January 1999, which is a non-provisional application of Application Serial No. 09/033,114, filed March 2, 1998, which is a continuation of U.S. Application Serial No. 08/733,850 filed October 18, 1996, now abandoned, which is a continuation of U.S. Application Serial No. 08/443,129 filed May 17, 1995, issued May 6, 1997 as U.S. Patent No. 5,627,073, which is a divisional application of U.S. Application Serial No. 08/286,304 filed August 5, 1994, issued November 5, 1996 as U.S. Patent No. 5,571,893, which is a continuation-in-part of U.S. Application Serial No. 08/233,609 filed April 25, 1994, issued July 9, 1996 as U.S. Patent No. 5,534,615, the entire disclosure of which is hereby incorporated by reference, which applications are incorporated herein by reference and to which applications priority is claimed under 35 USC §120, --

____ International Application _ filed on _ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

x and to provisional application No. 60/113,296 filed 22 December 1998, the entire disclosure of which is hereby incorporated by reference and to which application priority is claimed under 35 USC §119.--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		CLAIN	IS FOR FEE CA	LCULATION	7.77
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a) \$690.00
Total Claims	7	- 20 =	o	X \$18.00	\$0.00
Independent Claims	1	- 3=	0	X \$78.00	\$0.00
	Multiple d	ependent claim	+ \$260.00	\$0.00	
	\$690.00				

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$690. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this sheet is enclosed.</u>

9. Additional Papers Enclosed



Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations [x] Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence. A new Power of Attorney or authorization of agent. Other: 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications) [This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run] A petition, fee and/or response has been filed to extend the term in the pending prior application until A copy of the petition for extension of time in the *prior* application is attached. 11. **Correspondence Address:** _X_ Address all future communications to: GENENTECH, INC. Attn: Deirdre L. Conley 1 DNA Way

South San Francisco, CA 94080-4990

(650) 225-2066

Respectfully submitted, GENENTECH, INC.

Date: August 25, 2000

Deirdre L. Conley Reg. No. 36,487

1 DNA Way So. San Francisco, CA 94080-4990

Phone: (650) 225-2066 Fax: (650) 952-9881

